logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Pembrolizumab in combination with olaparib for treatment of metastatic squamous non-small cell lung cancer

< Back

Pembrolizumab in combination with olaparib for treatment of metastatic squamous non-small cell lung cancer

Drugs

Cancer and Palliative Care

September 2021


Pembrolizumab in combination with olaparib is in clinical development for the treatment of metastatic squamous non-small cell lung cancer (NSCLC). NSCLC makes up the majority of lung cancers in the UK and squamous NSCLC is where the cancer begins in the flat cells that cover the surface of the airway. Metastatic (advanced) NSCLC refers to when the cancer has spread from the lung to other parts of the body most often to the brain, bones, liver, and adrenal glands. Advanced squamous NSCLC is not usually curable and currently there are currently limited treatment options available for these patients.
Pembrolizumab is an immunotherapy drug given by intravenous (IV) infusion and works by blocking a protein called PD-L1, which results in an increased ability of the patient’s immune system to attack and kill cancer cells. Olaparib is taken orally and belongs to a class of drugs called poly-ADP-ribose polymerase inhibitors (PARPi) which increase the anti-cancer effect of immunotherapy drugs. The combined effect of both treatments may offer improved therapeutic benefits and an acceptable safety profile and if licenced, will offer an additional therapy option for metastatic squamous NSCLC patients.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts